The tumor suppressor p53 plays a pivotal role in the cellular response to DNA damage as it controls DNA repair, cell cycle arrest and apoptosis. We studied the autoregulation of human p53 gene transcription in colon cancer cell lines. Wild-type p53 has been shown to autoregulate its own transcription either positively or negatively and probably in a cell-type-speci®c manner. Indeed, a p53 binding site has been described in the human and murine p53 promoters, but a direct binding of wild-type p53 protein to this site has never been reported.
Introduction
Over the past several years, the role of the tumor suppressor gene p53 and its product in human cancer development has been clearly demonstrated (for review, see May and May, 1999) . Indeed, the p53 gene is one of the most frequently mutated genes in human malignancies (Hollstein et al., 1991; Levine et al., 1991; Vogelstein and Kinzler, 1992) . Its product, the wild-type (WT) p53 protein, plays an important role in the cellular response to DNA damage by controlling cell cycle and allowing repair of the altered genome (Hartwell, 1992; Lane, 1992) . The responses of the p53-dependent signaling pathways to dierent stresses such as anticancer drugs or irradiations have been extensively studied. Following DNA damage, p53 is modi®ed by a number of post-translational mechanisms such as phosphorylations, acetylations, glycosylations, protein interactions, redox mechanisms, subcellular localization, etc. These structural changes dramatically increase the half-life of p53, which accumulates rapidly in the nucleus. Moreover, the level of p53 can also be modulated at the transcriptional level after mitogenic stimulation, dierentiation induction and genotoxic stress (Reich and Levine, 1984; Sun et al., 1995; Balint and Reisman, 1996; Kirch et al., 1999) . The WT-activated p53 acts as a transcriptional factor and regulates the expression of target genes including p21(WAF1/CIP1), gadd45, bax or bcl2, which in turn control cell cycle checkpoints, DNA repair and apoptosis (Kern et al., 1991; Farmer et al., 1992; Miyashita et al., 1994) .
Surprisingly, little is known about the transcriptional autoregulation of p53 expression. Mosner et al. (1995) showed a negative feedback regulation of p53 on its own synthesis. The p53 mRNA can form a stable stemloop structure that involves the 5'-untranslated region (5'-UTR) as well as some 280 nucleotides of the coding sequence. The p53 protein binds to the 5'-UTR region and inhibits the translation of its mRNA. Another negative regulation of p53, in normal and cancer cells as well as after exposure to genotoxic agents, involved the product of the protooncogene Mdm2. Indeed, the Mdm2 gene is transcriptionally activated by p53. Mdm2 binds the N-terminal transactivation domain of p53, interferes with the recruitment of basal transcription machinery components and inhibits the transcriptional activity of p53. More importantly, Mdm2 binding can also lead to complete proteolytic degradation of p53 through the ubiquitin-proteasome pathway (Honda et al., 1997; Honda and Yasuda, 1999) .
Several oncoproteins, functioning as transcriptional factors, have been shown to autoregulate, negatively (C-Myc and C-Fos) or positively (C-Myb), the transcription of their encoding gene (Schonthal et al., 1989; Nicolaides et al., 1991; Facchini et al., 1997) . p53 gene transcriptional autoregulation has been studied by three dierent groups, who reported con¯icting results. Ginsberg et al. (1991) demonstrated that p53 protein down-modulated its own promoter. Dee et al. (1993) , on the other hand, showed that p53 transactivated its own promoter and identi®ed in the murine p53 promoter a domain responsive to the wild-type but not mutant p53. Finally, Hudson et al. (1995) suggested that p53 autoregulated its own transcription indirectly and in a cell-type-speci®c manner. None of these authors, however, could demonstrate a direct binding of p53 to its promoter, raising the possibility that WT p53 autoregulates its own transcription indirectly by interacting with other transcription factors. The existence of such a mechanism would also explain the fact that p53 regulated its own promoter in a cell-type-speci®c manner.
In this study, we con®rmed the transcriptional activation of human p53 promoter by p53 in human colorectal cancer cells. We identi®ed in the human p53 promoter another potential p53-responsive element that is required for p53 transcriptional autoactivation and was bound by p53 in vitro. We also showed an additive transcriptional eect of NF-kB subunits and p53 protein when acting together on the human p53 promoter.
Results

Wild-type p53 activates its own promoter
To investigate p53 transcriptional autoregulation, we studied the eect of WT p53 on its own promoter in HCT116 cells, a colon carcinoma cell line that harbors a wild-type p53 gene. HCT116 cells were cotransfected with the p53 WT-LUC reporter plasmid (Figure 1 ), which contains a 550-bp genomic fragment comprising the human p53 promoter and exon 1 upstream of the luciferase gene, and the p53 expression vector (pC53-SN3). As shown in Figure 2 , p53 transactivated its own promoter. The viability of the transfected cells and the transfection eciency were assessed by cotransfection with an RSV-bGAL construct, which contains the bgalactosidase gene (bGAL) driven by the rous sarcoma virus promoter (RSV).
p53 DNA-binding to p53 promoter As previously demonstrated, the anticancer drug daunomycin induced p53 activation and NF-kB nuclear translocation in HCT116 cells (Hellin et al., 1998) . Electrophoretic mobility shift assays (EMSA), performed with nuclear extracts from daunomycinstimulated or untreated HCT116 cells, showed an important increase in p53 binding to a p53 consensus probe ( Figure 3A, lanes 1 and 2) . Supershifting experiments performed with anti-p53 antibodies con®rmed the speci®city of this binding (lane 3).
According to previous reports (Dee et al., 1993; Hudson et al., 1995) , the p53 binding domain in the human p53 promoter is localized at positions 7166 to 7137 (with respect to the end of the untranslated exon 1) (Tuck and Crawford, 1989) and is linked to an NFkB binding site (Dee et al., 1993) (Figure 1 ). EMSA were performed with the same protein extracts and a probe corresponding to this putative p53 site. No direct binding was detected (data not shown), in agreement with previous results (Dee et al., 1993; Hudson et al., 1995) .
Interestingly, we identi®ed another potential p53-responsive element in the human p53 promoter, localized at positions 7217 to 7236, and its sequence was TTACTTGCCCTTACTTGTCA (Figure 1 ). We performed EMSA, with a probe corresponding to this site. As shown in Figure 3B , the daunomycin-induced p53 was able to bind this new p53 site (lanes 4 and 5). The speci®city of this binding was con®rmed by supershifting experiments with anti-p53 antibodies (lane 6). Moreover, competition experiments with unlabeled probes con®rmed this speci®city since only the wild-type p53RE probe, corresponding to the new p53 binding site, and the p53 consensus probe competed with p53 binding to this site whereas the mutated p53RE probe or an irrelevant probe failed to compete (lanes 7 ± 11). Finally, Figure 1 Luciferase reporter plasmid constructions. The p53 WT-LUC reporter plasmid contains a 550-bp genomic fragment including the human p53 promoter and exon 1 cloned in front of the luciferase gene. It harbors two potential p53 binding domains, one localized at positions 7217 to 7236 and one at positions 7166 to 7137 as well as one NF-kB binding site. Other luciferase reporter plasmids were constructed: p53RE WT-LUC contains only the p53-responsive element localized at positions 7217 to 7236 of the human p53 promoter; p53RE MT-LUC contains the same binding domain but mutated; p53 MT1-LUC contains the same sequence as p53 WT-LUC with a mutation of the p53 binding site localized at positions 7217 to 7236; p53 MT2-LUC contains the sequence from the p53 WT-LUC with a mutation of the NF-kB binding site Figure 2 Wild-type p53 activates its own promoter. HCT116 cells were cotransfected with the p53 WT-LUC (0.5 mg) reporter plasmid alone or together with an expression vector for p53 protein (pC53-SN3) in increasing amounts. The RSV-bGAL (0.4 mg) reporter plasmid was cotransfected in every well in order to monitor transfection eciency. LUC and bGAL activities were determined 24 h after transfection. LUC activity is expressed as fold induction relative to the activity observed with the reporter plasmid alone. Each value represents the mean of a minimum of three independent experiments after normalization to the bGAL activity p53 transcriptional autoactivation V Benoit et al the sequence-speci®city was con®rmed by the lack of p53-binding to a probe corresponding to the mutated p53RE site ( Figure 3C ). To identify the other bands observed with the p53RE probe, supershifting experiments were performed with antibodies directed against NF-kB subunits (p50, p65, c-Rel and RelB), against proteins known to bind to p53 site, like p73, or to interact with p53 (p300, CBP, HMG-1) and against irrelevant proteins like p21/WAF1, Bax and Bc12. These other bands were not supershifted by any of these antibodies (data not shown).
Function of a new p53-responsive element of the human p53 promoter
In order to demonstrate the function of this new p53 binding site (p53RE) in transient transfection assays, we constructed two luciferase (LUC) reporter plasmids containing this p53-responsive element (p53RE), either wild-type or mutated, and named them p53RE WT-LUC and p53RE MT-LUC, respectively ( Figure 1 ). HCT116 cells were cotransfected with one of these reporter plasmids and the p53 expression vector (pC53-SN3) in increasing amounts. As illustrated in Figure  4A , p53 was able to induce LUC activity through this p53 binding site, but no transactivation was observed with the mutated binding site. To con®rm these results, we constructed a luciferase reporter plasmid harboring the entire human p53 promoter mutated at the p53RE (p53 MT1-LUC) ( Figure 1 ). Transient transfection assays were performed under the same conditions and showed that this p53RE was essential for p53 autotransactivation ( Figure 4B ).
p53 autoregulation in HCT116MT9 cells
Interestingly, the level of LUC transcription was lower with the p53RE WT-LUC as compared to p53 WT-LUC, indicating that an additive sequence could be necessary for optimal transactivation by p53. Since the human p53 promoter harbors an NF-kB binding site, we examined the role of NF-kB in p53 autoregulation. The HCT 116 cells were stably transfected with an expression vector coding for a dominant-negative IkBa protein mutated at serines 32 and 36 (HCT116MT9) (Hellin et al., 1998) . The mutated IkBa is resistant to both phosphorylation and proteolytic degradation, leading to NF-kB sequestration in the cytoplasm. By EMSA analysis, we previously demonstrated that nuclear induction of NF-kB was not detected in HCT116MT9 cells after daunomycin, TNF-a or IL1b stimulation (Hellin et al., 1998) . HCT116MT9 cells were transiently cotransfected with either p53 WT-LUC, p53RE WT-LUC or p53RE MT-LUC, and wild-type p53 expression vector (pC53-SN3) in increasing amounts. First, we observed a lower level of p53-induced LUC activity through the p53 WT-LUC reporter plasmid in HCT116MT9 cells as compared to HCT116 cells ( Figure 5A compare to Figure 2 ). Transfection of a p21 promoter-LUC construct, including a p53 consensus responsive element, in HCT116 and HCT116MT9 cells showed similar p53-induced transactivation levels, therefore indicating that the lower p53 transactivating activity in HCT116MT9 cells was promoter-speci®c and probably linked to NF-kB inhibition (Hellin et al., unpublished data) . In HCT116MT9 cells, the level of p53-induced transcription with the p53 WT-LUC was very low and not signi®cantly dierent from that observed with the p53RE WT-LUC. As expected, the autoactivation was completely abolished when the p53 binding site was mutated.
We then constructed a luciferase reporter plasmid harboring the entire human p53 promoter mutated at the NF-kB binding site, named p53 MT2-LUC ( Figure  1) . The HCT116 cells were cotransfected with p53 WT- Figure 5B ). We observed a lower level of p53-induced LUC activities with the promoter containing a mutated NF-kB site as compared to the whole WT promoter. All these results strongly suggested the existence of a cooperative eect of NF-kB and p53 in p53 autoregulation.
Additive effect of NF-kB and p53 in p53 transcriptional regulation
To better unravel the role of NF-kB in p53 autoregulation, we cotransfected HCT116 cells with p53 WT-LUC ( Figure 6A ) or p53 MT2-LUC ( Figure  6B ) with a constant amount of p53 expression plasmid and increasing amounts of RelA NF-kB subunit expression plasmid. A clear additive eect of RelA subunit and p53 was observed, and this cooperative eect was abolished when the NF-kB binding site was mutated. A cooperative eect was also observed when other NF-kB subunits, such as p50/RelA heterodimers and c-Rel subunits, were cotransfected (data not shown). Similar experiments were performed on other human tumor cell lines: MCF7 human breast adenocarcinoma cells, SK-OV-3 human ovarian adenocarcinoma cells and Saos-2 human osteogenic sarcoma cells. In all three cell lines, p53 transactivated its own promoter in a dose dependent-manner while NF-kB subunits had an additive eect with p53 in SK-OV-3 and Saos-2 cells, thus con®rming that the observed eect was not peculiar for the HCT116 cells (data not shown).
Effect of daunomycin on p53 transcriptional regulation
In HCT116 cells, daunomycin is an activator of endogenous p53 and NF-kB (Hellin et al., 1998) . To study the additional eect between these two transcription factors in response to pharmacological stimulation, HCT116 cells were transfected with p53 WT-LUC, p53 MT1-LUC (p53 mutated site) or p53 MT2-LUC (kB mutated site). Transfected cells were then treated with 1 or 2 mM daunomycin for 6 h. In these conditions, a slight but signi®cant transactivation was observed with the p53 WT-LUC reporter in response to 1 mM (P50.05) and 2 mM (P50.01) daunomycin. With the p53 MT2-LUC reporter, this activation remained signi®cant (P50.05 and 0.01 in response to 1 and 2 mM daunomycin respectively) and was weaker than the one obtained with the p53 WT-LUC reporter Figure 4 Function of the p53-responsive element. (A) HCT116 cells were cotransfected with the p53RE WT-LUC (0.5 mg) or p53RE MT-LUC (0.5 mg) reporter plasmid alone or together with an expression vector for the p53 protein (pC53-SN3) in increasing amounts. The RSV-bGAL (0.4 mg) reporter plasmid was cotransfected in every well in order to monitor transfection eciency. LUC and bGAL activities were determined as described in Figure 2. (B) HCT116 cells were cotransfected with the p53 WT-LUC (0.5 mg) or p53 MT1-LUC (0.5 mg) reporter plasmid alone or together with an expression vector for p53 protein (pC53-SN3) in increasing amounts. LUC and bGAL activities were determined as described in Figure 2 Figure 5 p53 autoregulation in HCT116MT9 cells. (A) HCT116MT9 cells were cotransfected with the p53 WT-LUC (0.5 mg), p53RE WT-LUC (0.5 mg) or p53RE MT-LUC (0.5 mg) reporter plasmid alone or together with an expression vector for p53 protein (pC53-SN3) in increasing amounts. The RSV-bGAL (0.4 mg) reporter plasmid was cotransfected in every well in order to monitor transfection eciency. LUC and bGAL activities were determined as described in Figure 2. (B) HCT116 cells were cotransfected with the p53 WT-LUC (0.5 mg) or p53 MT2-LUC (0.5 mg) reporter plasmid alone or together with an expression vector for p53 protein (pC53-SN3) in increasing amounts. LUC and bGAL activities were determined as described in Figure 2 p53 transcriptional autoactivation V Benoit et al in response to 2 mM daunomycin treatment. No activation was observed with the p53 MT1-LUC indicating that the p53RE site is required for the daunomycin-induced transcriptional activation of the p53 promoter while the mutation of the kB site only partially prevented daunomycin-dependent promoter response.
Discussion
The p53 protein plays an important role in the cellular response to DNA damage by controlling DNA repair, cell cycle arrest and apoptosis p53 expression is regulated mostly by post-translational modi®cations such as phosphorylation and interaction with other proteins. However, transcriptional and translational modulation also seems to be involved in the control of p53 activity (reviewed in Hansen and Oren, 1997; Oren, 1999) . Several transcriptional factors (AP-1, NF-kB, Myc/Max) as well as p53 itself have indeed been reported to interact with the p53 gene promoter (Kirch et al., 1999) . However, there is no consensus regarding the role of p53 in the regulation of its own transcription. Contradictory reports have claimed that p53 could either inhibit or enhance transcription through its own promoter. These discrepancies concerning the autoregulation of the p53 promoter could be due to distinct experimental systems. In their experiments, Ginsberg et al. (1991) reported that p53 inhibited its gene promoter (as well as other gene promoters) in rat embryo ®broblasts and hypothesized that this eect was related to p53 interactions with other transcription factors. Another group published that murine p53 transactivated its own promoter through a p53-responsive element, but failed to detect any p53 DNA binding to this sequence (Dee et al., 1993) . Finally, Hudson et al. (1995) reported an inhibition of p53 gene transcription in Saos-2 and K562, but not in DP15 human cell lines. Contrary to Hudson, we showed that, in Saos-2 cells, p53 transactivated its own promoter and that NF-kB subunits had an additive eect. These discrepancies could be explained by the promoter sequence used by Hudson et al. (1995) . Their construct did not include the new p53-responsive element we identi®ed. All these authors did not detect any p53 DNA binding activity to the p53 putative binding sequence that they identi®ed at positions 7166 to 7137 in the human promoter, and thus concluded that this p53 inhibitory activity was indirect.
In the present study, we have demonstrated a transcriptional activation of human p53 promoter by the p53 protein in human cancer cells and identi®ed a new p53-responsive element in this promoter. Interestingly, this p53-responsive element was localized at positions 7217 to 7236 and was thus dierent from the one previously described. Its mutation abolished transactivation by p53 and, for the ®rst time, we could demonstrate p53 DNA binding to a de®ned sequence from its own promoter. Therefore, our data indicate that, in some circumstances, human p53 positively and directly regulates its own promoter through DNA binding to a p53-responsive element. However, under dierent experimental conditions, p53 could possibly in¯uence its own promoter activity through indirect mechanisms. Indeed, several studies reported that p53 indirectly regulates gene activity by binding to the TATA box binding proteins (TBP or TFIID) (Seto et al., 1992; Liu et al., 1993; Truant et al., 1993) . p53 can also modify the activity of other transcription factors either by directly interacting with them or by regulating their expression or activity. For example, the association of p53 with p300 inhibits other p300-dependent factors such as AP-1 or hypoxia-inducible factor-1 Figure 6 Additive eect of NF-kB and p53 on the p53 promoter. (A) HCT116 cells were cotransfected with p53 WT-LUC (0.5 mg) and RSV-bGAL (0.4 mg) reporter plasmids together with p53 expression vector (pC53-SN3, 10 ng) and/or RelA expression vector in increasing concentrations. LUC and bGAL activities were determined as described in Figure 2. (B) HCT116 cells were cotransfected with p53 MT2-LUC (0.5 mg) and RSVbGAL (0.4 mg) reporter plasmids together with p53 expression vector (pC53-SN3, 10 ng) and/or RelA expression vector in increasing concentrations. LUC and bGAL activities were determined as described in Figure 2 Figure 7 Eect of daunomycin on p53 transcriptional regulation. HCT116 cells were cotransfected with p53 WT-LUC (0.5 mg), p53 MT1-LUC (0.5 mg) or p53 MT2-LUC (0.5 mg) reporter plasmids together with RSV-bGAL (0.4 mg). Transfected cells were treated with 1 or 2 mM daunomycin for 6 h. LUC and bGAL activities were determined as described in Figure 2 (HIF1a) (Avantaggiati et al., 1997; Blagosklonny et al., 1998) . The p53/Sp1 complex displays, in vitro, a high anity for Sp1 or p53 consensus sites and positively regulates target gene expression (Borellini and Glazer, 1993; Gualberto and Baldwin, 1995) , while the association between p53 and WT1 increases p53 stability, its transcriptional activity and gadd45 expression (Zhan et al., 1998) .
The interaction between p53 and NF-kB is another example of the complexity and cellular speci®city of p53 functions. In response to cellular treatment with DNA-damaging agents (ionizing radiations or cytotoxic drugs), these two transcription factors are activated through post-translational regulations. Although the kinetics of their activations are not exactly parallel, active p53 and NF-kB are coexpressed for some time in the nuclei of these cells and are both believed to play an important biological role in the response to DNA damage and thus to anticancer therapies. According to several recent studies, NF-kB and p53 have antagonistic roles in the control of apoptosis in response to DNA damage. Indeed, NF-kB activation by daunomycin, camptothecin or ionizing radiations inhibits apoptosis through the transactivation of antiapoptotic genes (Van Antwerp et al., 1996; Wang et al., 1996 Wang et al., , 1999 . Moreover, it has been reported that NF-kB prevents p53-dependent transactivation through a competition for the coactivators p300 and CBP (Ravi et al., 1998; Wadgaonkar et al., 1999; Webster and Perkins, 1999) . However, one cannot rule out that these two transcription factors may also have additional or synergistic eects in some cells or on some gene promoters. NF-kB has been shown to be required for the onset of apoptosis in a few experimental systems (Lin et al., 1995; Grilli et al., 1996; Baichwal and Baeuerle, 1997) and is required for p53-dependent apoptosis (Ryan et al., 2000) .
Our study indicates that the two transcription factors exert additional eects in transactivating the p53 gene promoter through their respective binding sites. Moreover, NF-kB seems to exert an additional role by indirect mechanisms. Indeed, the p53 WT-LUC was hardly transactivated by p53 in HCT116MT9 ( Figure 5A ), while the p53 MT2-LUC, containing a mutated kB binding site, is still transactivated by p53 in HCT116 cells ( Figure 5B ). It thus seems that NF-kB could play a double role in the p53-dependent activation and could act via its speci®c binding site and through indirect mechanisms. NF-kB could increase p53 transactivating activity, for example, by inducing a cofactor or by sequestering a p53 inhibitor. Such an eect would also explain the weak transactivation of a p53RE-LUC reporter by p53 in HCT116MT9 cells.
Based on our data, a model may be proposed for p53 gene regulation by NF-kB and p53 in response to DNA damage. In normal cells, NF-kB is rapidly activated and inhibits the onset of apoptosis, thus allowing the cell to launch the DNA repair mechanisms. NF-kB activity also maintains or weakly induces p53 gene transcription. Such a transcription is required for continuous p53 synthesis simultaneously with its post-translational modi®cations and stabilization. The p53 protein also participates in the transcriptional regulation of its own promoter and induces the transcription of its target genes responsible for cell cycle arrest, DNA repair and p53 degradation. Finally, as the transient NF-kB activation vanishes, apoptosis can be activated by p53-independent or -dependent mechanisms. In cancer cells, however, this tightly regulated scheme could be perturbed either by p53 mutations or p53 degradation or by constitutional or sustained NF-kB activation, as described in EBVtransformed B lymphocytes, in Hodgkin's disease cells or in some breast cancer cells (Bargou et al., 1997; Sovak et al., 1997) .
Materials and methods
Recombinant plasmids
The p53 WT-LUC (wild-type p53 promoter luciferase reporter), which contains a 550-bp genomic fragment including the human p53 promoter and exon 1 in front of the luciferase gene, was kindly provided by ET Stuart (Stuart et al., 1995) . The PMT2T expression vector encoding the RelA NF-kB subunit was previously described (Bours et al., 1992) . The expression vector for wild-type p53 (pC53-SN3) was provided by Dr U Gullberg (University of Lund, Sweden). The RSV-bGAL plasmid was kindly supplied by Dr R Winkler (University of LieÁ ge, Belgium). The p53RE WT-LUC and the p53RE MT-LUC were constructed by inserting oligonucleotides at the XhoI and MluI sites of the pGL3 promoter plasmid (Promega, Madison, WI, USA). The p53 MT1-LUC and the p53 MT2-LUC were obtained from the p53 WT-LUC by using the GeneEditor In Vitro SiteDirected Mutagenesis System (Promega, Madison, WI, USA). Compared to the original plasmid, the p53 MT1-LUC is mutated at the p53-responsive element (TTAT-TAACCCTTACTTGTCA in place of TTACTTGCCCT-TACTTGTCA), while the p53 MT2-LUC is modi®ed at the kB site (GAATTTTTCCCC in place of GGGGTTT-TCCCC). All constructions were checked by sequencing.
Cell culture and transfections
HCT116 human colon carcinoma cells (ATCC CCL247) were grown in McCoy's 5A modi®ed medium supplemented with 1% L-glutamine, 1% antibiotics and 10% fetal bovine serum (Life Technologies, Grand Island, NY, USA). HCT116MT9 cells (Hellin et al., 1998) were grown in the same medium supplemented with G418 (geneticin, 0.5 mg/ml active concentration, Roche, Mannheim, Germany). Cells were exposed to daunomycin (Cerubidine, Rhone-Poulenc Rorer) at 1 mM for the indicated times.
For DNA transfection, cells were plated at a density of 7.10 5 cells per 35-mm diameter well culture dishes and transfected 24 h later with FuGENE (Roche, Mannheim, Germany). We transfected 0.5 mg of reporter plasmid, 0.4 mg of RSV-bGAL and dierent amounts of p53 or NF-kB expression vectors. The total amount of transfected DNA was kept constant by addition of empty PMT2T expression vector. We used 1.5 ml FuGENE per mg of transfected plasmid. Cells were harvested and lysed 24 h after transfection for determination of LUC or bGAL activities. Cotransfection of RSV-bGAL was used to normalize transfection ecacy and cellular viability of transfected cells.
To study the eect of daunomycin on p53 promoter induction, transfected cells were treated with 1 or 2 mM daunomycin for 6 h and then harvested and lysed.
Reporter plasmid assay
Luciferase activity (LUC) was determined with the Luciferase Reporter Gene Assay Kit (Roche, Mannheim, Germany) as recommended by the manufacturer. b-Galactosidase activity (bGAL) was determined with the chemoluminescent bGal p53 transcriptional autoactivation V Benoit et al
Reporter Gene Assay Kit (Roche, Mannheim, Germany) as described by the manufacturer.
Protein extraction and electrophoretic mobility shift assay (EMSA)
Nuclear protein extracts were prepared as previously described (Hellin et al., 1998) . Protein amounts were quanti®ed with the Micro BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). The p53 EMSA were performed as described (Hainaut and Milner, 1993) . Five micrograms of nuclear extract were mixed with 9 ml of binding buer (HEPES pH 7.6 20 mM, NaCl 10 mM, MgCl 2 1.5 mM, EDTA 0.2 mM, glycerol 20%, NP-40 0.1%, DTT 1 mM and PMSF 0.5 mM), 0.6 ml DTT, 2 ml salmon sperm, 1 ml BSA and the 32 P-labeled probe. In order to increase the p53-speci®c DNA binding and to improve detection of the p53-speci®c band, 1 ml of the anti-p53 antibody 421 was added to each sample. The samples were then incubated for 30 min at room temperature and loaded on a 4% acrylamide gel.
For supershifting experiments, 1 ml of the anti-p53 antibody 1801 (Oncogene Research Products, Cambridge, MA, USA) was added before incubation.
The oligonucleotides used for EMSA had the following sequences: 5'-TTGGCGGACATGCCCGGGCATGTCCG-3' for the p53 consensus probe (CS), 5'-TTGGGGAT-TACTTGCCCTTACTTGTCATGGCGACTGT-3' for the wild-type p53RE probe (WT) and 5'-TTGGGGATTAT-TAACCCTTACTTGTCATGGCGACTGT-3' for the mutated p53RE probe (MT).
